The DOI matches its Crossref record.
Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients
Abstract
Many randomized trials have evaluated α‐interferon as myeloma therapy, some suggesting a benefit and others not. Most were too small to give reliable answers, so a systematic overview has been performed to provide a more reliable estimate of the effect of interferon. The main end‐points were response rates (induction trials), progression‐free survival (PFS) and overall survival (OS). Individual patient data were supplied for 24 trials involving 4012 patients, 12 induction trials (2469 patients) and 12 maintenance trials (1543 patients). In induction, response rates were slightly better with interferon (57·5% versus 53·1%, P = 0·01). PFS was better with interferon (33% versus 24% at 3 years, P < 0·00001), an effect seen in both induction (P = 0·0003) and maintenance (P < 0·00001) trials. Median time to progression was increased by about 6 months in both settings. OS was somewhat better with interferon (53% versus 49% at 3 years, P = 0·01) with median survival increased by about 4 months. This benefit was restricted to the smaller trials. The effect of interferon was not significantly related to the dose or duration of interferon or to patients' characteristics. PFS was improved with interferon, but the survival benefit, if any, was small and needs balancing against cost and toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,296
Raab, M. S., Podar, K., Breitkreutz, I., Richardson, P. G., & Anderson, K. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60221-x · Cited by 697
Röllig, C., Knop, S., & Bornhäuser, M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60493-1 · Cited by 603
Simmonds, M. C., Higginsa, J. P. T., Stewartb, L. A., Tierneyb, J. F., Clarke, M. J., & Thompson, S. G. (2005) · Clinical Trials · doi:10.1191/1740774505cn087oa · Cited by 555
Barlogie, B., Kyle, R. A., Anderson, K. C., Greipp, P. R., Lazarus, H. M., Hurd, D. D., McCoy, J., Moore, D. F., Dakhil, S. R., Lanier, K. S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5807 · Cited by 495
Metadata
- Authors
- The Myeloma Trialists' Collaborative Group
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2001-06
- Volume
- 113
- Issue
- 4
- Pages
- 1020-1034
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W4235854784
- Cited by
- 217
- References
- 0
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. https://app.cochat.ai/papers/10.1046/j.1365-2141.2001.02857.x
- The paper
- The Myeloma Trialists' Collaborative Group. (2001). Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. British Journal of Haematology. https://doi.org/10.1046/j.1365-2141.2001.02857.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.